Core Viewpoint - Sairun Pharmaceutical (002898) has issued a warning regarding the risk of delisting due to expected negative profits and revenues for the fiscal year 2024, following a significant revision of its earnings forecast [1][4]. Financial Performance - The company initially projected 2024 revenues between 270 million to 320 million yuan, with a net profit of 4.5 million to 6.5 million yuan, but later revised these figures to revenues of 255 million to 270 million yuan and a net loss of 21 million to 41 million yuan [2][6]. - The revision was attributed to the decision to not recognize certain sales revenues, resulting in a reduction of approximately 39.63 million yuan in revenue and 33.96 million yuan in gross profit [3][6]. Historical Context - Sairun Pharmaceutical has a history of revising its earnings forecasts, having made multiple adjustments from 2021 to 2023, indicating ongoing issues with revenue recognition standards [5][6]. - The company has reported losses in most years since 2020, with only 2023 showing a profit of 9.534 million yuan, while losses for 2020, 2021, and 2022 were 67.22 million, 23.34 million, and 37.31 million yuan respectively [6]. Market Dynamics - The company’s main products contribute significantly to its revenue, but they face intense competition, with numerous generic alternatives available in the market [7]. - Despite winning bids in national drug procurement, the expected revenue growth has not materialized, leading to continued financial pressure [8][9]. Strategic Response - Sairun Pharmaceutical acknowledges the challenges posed by drug price reductions due to centralized procurement and aims to leverage its full industry chain advantages to enhance market presence and profitability [10]. - The company plans to improve its financial reporting and investor communication to restore confidence amid the risk of delisting [10].

Core Viewpoint - Despite announcing a collaboration with Novo Nordisk for the weight loss drug UBT251, the stock price of Federated Pharmaceutical fell significantly due to disappointing financial results for 2024, which showed a decline in net profit [3][4]. Financial Performance - Federated Pharmaceutical reported a revenue of 13.76 billion RMB for 2024, a slight increase of 0.14% year-on-year [7]. - The company's net profit attributable to shareholders was 2.66 billion RMB, reflecting a decrease of 1.54% compared to the previous year [7]. - The earnings per share decreased by 1.5% to 146.39 RMB [5]. Business Segments - Revenue from intermediate products increased by 1.8%, while revenue from raw materials and formulation products decreased by 0.5% and 5.9%, respectively [7]. - The significant decline in the formulation business was attributed to price reductions due to national drug procurement policies, alongside a 26.6% increase in R&D expenses for formulation products [7]. Key Product Developments - The UBT251 drug, developed by Federated Pharmaceutical, is currently in early clinical development and aims to treat obesity and type 2 diabetes [3][9]. - The company is the first in China and the second globally to have a long-acting GLP-1/GIP/GCG tri-target agonist approved for clinical trials using chemical synthesis methods [9]. - Sales of diabetes products reached 1.25 billion RMB in 2024, marking a 9.5% increase year-on-year, with insulin product sales benefiting from a significant increase in procurement volume [8].

四川百利天恒药业股份有限公司 上市公告书 股票简称：百利天恒 股票代码：688506 四川百利天恒药业股份有限公司 上市公告书 特别提示 四川百利天恒药业股份有限公司（以下简称"百利天恒"、"发行人"、"公 司"或"本公司"）股票将于 2023 年 1 月 6 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上 市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 四川百利天恒药业股份有限公司 （成都市温江区成都海峡两岸科技产业园百利路 161 号一幢一号） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） （广东省深圳市福田区福田街道福华一路 119 号安信金融大厦） 二〇二三年一月五日 1 四川百利天恒药业股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法 承担法律责任。 上海证券交易所（以下简称"上交所"）、有关政府机关对本公司股票上市 及有关事项的意见，均不表明对本公司的任何保证。 本 公 司 ...